Jason Drew Smith Sells 1,519 Shares of Urogen Pharma (NASDAQ:URGN) Stock

Urogen Pharma (NASDAQ:URGN) General Counsel Jason Smith sold 1,519 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $42.54, for a total transaction of $64,618.26. Following the transaction, the general counsel directly owned 53,141 shares of the company’s stock, valued at $2,260,618.14. This represents a 2.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Urogen Pharma Stock Down 6.1%

Shares of URGN stock opened at $42.24 on Friday. Urogen Pharma has a 52-week low of $15.86 and a 52-week high of $50.81. The stock has a market cap of $2.06 billion, a PE ratio of -21.33 and a beta of 1.57. The business has a 50-day simple moving average of $43.24 and a 200-day simple moving average of $31.46.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The business had revenue of $72.46 million during the quarter, compared to analyst estimates of $63.55 million. Sell-side analysts anticipate that Urogen Pharma will post -0.2 earnings per share for the current fiscal year.

Institutional Trading of Urogen Pharma

Institutional investors have recently modified their holdings of the stock. Osaic Holdings Inc. lifted its position in Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after acquiring an additional 3,070 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in Urogen Pharma during the 2nd quarter worth approximately $66,000. Russell Investments Group Ltd. grew its position in Urogen Pharma by 1,594.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after buying an additional 3,125 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Urogen Pharma in the second quarter valued at about $78,000. Finally, Tower Research Capital LLC TRC increased its position in Urogen Pharma by 422.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock worth $94,000 after purchasing an additional 5,571 shares during the period. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on URGN shares. UBS Group reaffirmed a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research note on Friday, July 17th. HC Wainwright increased their price target on shares of Urogen Pharma from $45.00 to $75.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Jefferies Financial Group reissued a “buy” rating and set a $56.00 price objective on shares of Urogen Pharma in a research report on Thursday. Finally, Guggenheim lifted their target price on shares of Urogen Pharma from $42.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $52.38.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.